Revvity (RVTY) said Thursday it has signed a new agreement with Genomics England to further collaborate on the Generation Study, a national initiative to screen up to 100,000 newborns for more than 200 rare genetic disorders.
Under the new contract, Revvity said it will also provide DNA sequencing services to help screen newborns for rare genetic conditions, adding to its previous DNA extraction services.
The firm said it will now be able to provide an end-to-end solution with a localized lab facility to advance the screening process.
Price: 107.11, Change: -2.81, Percent Change: -2.56
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。